Zynerba Pharmaceuticals, Inc. Price Today
Zynerba Pharmaceuticals, Inc.
ZYNE
Healthcare
$18.94M
💰
Market Cap
0
💸
Price to Earnings
$-0.8
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
3 |
Strong Buy |
4 |
Hold |
2 |
Sell |
0 |
Strong Sell |
0 |
ZYNE Price Forecast Target
0.4 👉 10.0 +2733%
ZYNE EPS Forecast
-0.8 👉 -0.6 +-25%
Financials
Profit Margin
0 %
Revenue Growth
0 %
Dividend
$ 0
Held Percent
6.1% - Insiders
12.1% - Institutions
81.8% - Public
Major Fund Holders
-
💰 Vanguard Group Inc $937,228.0
-
💰 Blackrock Inc. $360,641.0
-
💰 ETF Managers Group, LLC $310,954.0
-
💰 Renaissance Technologies, LLC $244,971.0
-
💰 Millennium Management Llc $196,230.0
Stock Ideas
Ron Baron Portfolio
Ron Baron is an American billionaire investor, entrepreneur, and the founder of Baron Capital Group, a well-known investment management firm. He is recognized for his long-term, growth-oriented investment approach and has built a successful track re…
Scott Ferguson Portfolio
With a strong background as a protégé of Bill Ackman, founder of Pershing Square Capital Management, Scott Ferguson has honed his skills and expertise in the art of activist investing. He possesses the ability to identify undervalued companies with …
Ken Fisher Portfolio
Ken Fisher is a prominent American investment analyst, author, and the founder of Fisher Investments, a global investment firm managing billions of dollars in assets for individual and institutional clients. As a highly successful investor and fina…
Jim Simons Portfolio
Jim Simons, the mastermind behind the Medallion Fund, has achieved such extraordinary returns that he has skyrocketed to the ranks of the world's wealthiest individuals. The secret to his success lies in the fund's implementation of high-frequency t…📮FAQ
Some Frequently Asked Questions.
The Zynerba Pharmaceuticals, Inc. industry is Drug Manufacturers—Specialty & Generic
The Zynerba Pharmaceuticals, Inc. sector is Healthcare
The Zynerba Pharmaceuticals, Inc. forecasted predicted Price to Earnings PE ratio is -0.6
The Zynerba Pharmaceuticals, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Zynerba Pharmaceuticals, Inc. is $18.94M
There are total of 46681585 float shares with 12.1% held by Institutions and 6.1% held by insiders
The MZynerba Pharmaceuticals, Inc. forecasted Earnings per Share EPS is $-0.6
The Zynerba Pharmaceuticals, Inc. Earnings per Share EPS is -0.8
The Zynerba Pharmaceuticals, Inc. company has $0 gross profits with 0 profit margins
The Zynerba Pharmaceuticals, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Zynerba Pharmaceuticals, Inc. Revenue is $0 with 0 revenue growth
The price target for Zynerba Pharmaceuticals, Inc. stock is $10.0 for the high target and $0.4 for the low target
The consensus analyst recommendations for Zynerba Pharmaceuticals, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Zynerba Pharmaceuticals, Inc. is Buy, with the following breakdown:
- Buy: 3
- Strong Buy: 4
- Hold: 2
- Sell: 0
- Strong Sell: 0
The Beta of Zynerba Pharmaceuticals, Inc. is 1.8
The dividend of Zynerba Pharmaceuticals, Inc. is $0
The dividend yield of Zynerba Pharmaceuticals, Inc. is 0%
The biggest institutional and mutual fund holders of Zynerba Pharmaceuticals, Inc. stock are
- Vanguard Group Inc
- Blackrock Inc.
- ETF Managers Group, LLC
- Renaissance Technologies, LLC
The Zynerba Pharmaceuticals, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0